


Outline




- **Introduction to influenza**
- **Avian influenza**
- **Swine influenza and influenza in neglected species**
- **Vaccination of animals (and humans)**
- **Surveillance and legislation on influenza in Europe**



Influenza A virus

- *Orthomyxoviridae* family
- Single stranded RNA segmented genome



- Subtypes 16 HA, 9 NA major antigenic types in birds
 - H5N1
 - H7N1
 - H1N1
 - Etc.




- Non-avian hosts eg.:
 - Swine: H1N1, H1N2, H3N2
 - Human: H1N1, H1N2, H3N2
 - Horse: H3N8



Influenza A virus evolution

- Drift
 - Point mutations, RNA polymerase without proof-reading activity

- Shift/reassortment



- Species jump followed by adaptation





Figure 1. Possible transmission pathways for avian influenza.

Influenza A virus host range



Mänz B et al. J. Virol. 2013;87:7200-7209

Low and highly pathogenic avian influenza A viruses



Bird flu

H1,H2,H3.....H16


H5,H7

Low pathogenic influenza (LPAI) often result in no or little clinical disease in poultry


Highly pathogenic influenza (HPAI) result in up to 100 % mortality in 48 hours in some poultry species




H5 & H7 AIVs transmissions



Where is avian influenza detected?




Wild birds can act as vectors for AI virus



Intercontinental spread of HPAI H5N8 viruses

Lee et al. (2015) Journal of Virology



HPAI as a zoonosis



Bird flu and danger to humans

Bird flu, or avian flu, has a high mortality rate in humans, but as of yet, can ~~not~~ be transmitted from person to person. ... WHO, February 20th, 2006: "Human infections remain a rare event."

Infection with type A virus H5N1

- 1 Most virulent bird flu virus; mutates rapidly, altering its genetic material
- 2 Humans infected by close contact with live infected poultry
- 3 Birds carry virus and excrete it in feces, which dries, becomes pulverized and then can be inhaled or taken in by touch
- 4 Humans have no immunity against this virus

Symptoms

Similar to common influenza

- Fatigue
- Fever
- Conjunctivitis


Sore throat

Cough

Muscle aches

When untreated

Rapid deterioration; viral pneumonia leading to respiratory distress, kidney failure, multi-organ failure, death



Reason for concern


Humans infected with bird flu could serve as a host for a new genetic subtype that can be transmitted from person to person



Might start influenza pandemic



Avian Influenza Human Cases




H5N8

- No reported cases, but some H5N6 positive human cases in Korea




H5 evolution - drift


Evolution of the Asian H5 Hemagglutinin




When discrete monophyletic groups begin to appear within a specific clade and those groups meet the nucleotide divergence criteria (as well as having bootstrap values >60), they are split into second order clades (but still considered part of the original first order clade). As a second order clade continues to evolve it may reach a similar level of genetic diversity at which point it may be split into third order clades and so on. The same clade designation criteria apply to first, second, and any higher order clade designations.




1996-2001




1996-2004



1996-2005



1996-2008



1996-2011

The bloody past of the H5 gd-like viruses

- 1996 H5N1 China geese
- 1997 H5N1 Hong Kong Poultry, wild birds and humans
- 2004 H5N1 Asia Poultry and wild birds
- 2005 H5N1 Quinhai Lake 60.000 dead waterbirds
- 2006 H5N1 Europe 55 different countries incl. DK
- 2006-12 H5N1 Only Asia

- 2014 H5N8 S. Korea 19 mill. birds killed

- 2014 H5 clade 2.3.4.4 reassorted with N2, N3, N6 and N8 in China

- 2014-18 H5N8 Europe and N. America.....clade 2.3.4.4
- H5N2 N. America.....clade 2.3.4.4
- H5N6 Europe.....clade 2.3.4.4

Vaccines against avian influenza virus

- Classical 1st. and 2nd. generation vaccines

| Vaccine Platform | Advantages | Disadvantages |
|--------------------------|--|---|
| Inactivated vaccines | <ul style="list-style-type: none"> • Safe | <ul style="list-style-type: none"> • Limited immunogenicity • Short-lasting immunity • Often multiple doses required • Poor induction cellular immunity |
| Subunit vaccines | <ul style="list-style-type: none"> • Safe • Selection of antigen possible | <ul style="list-style-type: none"> • Limited immunogenicity • Short-lasting immunity • Poor induction cellular immunity |
| Live attenuated vaccines | <ul style="list-style-type: none"> • Present conformational epitopes • Single dose sufficient • Induction cellular immunity | <ul style="list-style-type: none"> • Safety risk in immunocompromized • Reversion to wildtype possible • Interference by maternal antibodies |

Vaccines against avian influenza virus

- 3rd generation vaccines

| | | |
|-----------------------|--|---|
| Virus-like particles | <ul style="list-style-type: none"> • Safe • Present conformational epitopes | <ul style="list-style-type: none"> • Complicated production process |
| DNA vaccines | <ul style="list-style-type: none"> • Present conformational epitopes • Selection of antigen possible • Induction cellular immunity • Effective in heterologous prime-boost | <ul style="list-style-type: none"> • Often poorly protective when used exclusively |
| Vector-based vaccines | <ul style="list-style-type: none"> • Safe • Present conformational epitopes • Selection of antigen possible • Induction humoral and cellular immunity • Effective in heterologous prime-boost | <ul style="list-style-type: none"> • Often multiple doses required • Interference by vector-specific immunity |

Recombinant viral-vectored vaccines - examples

- **Fowlpox-AIV vaccines**

- Used for H5 LPAI in Mexico
- Limited transmission to unvaccinated animals
- Low antibody response as measured by HI test
- Good cellular response
- Can be used in 1-day old animals (bypass MDA)
- DIVA possible (ELISA)

- **NDV-AIV**

- China and Mexico against H5 HPAI
- Primer-boost necessary
- Cannot be used in very young animals
- Transmission to unvaccinated animals

- **Alfavirus-AIV (RNA vaccine)**

- Only one replication cycle – no transmission
- Commercial available for swine influenza in USA
- Stock-piled in the US after the 2014/15 outbreak

Vaccines – long range perspectives/sweet dreams

- One vaccine for all subtypes
 - Conserved part of the HA
 - NA targeted vaccines
 - Vaccines targeting other proteins
 - RNA polyvaccines
- Primer-boost vaccine strategy
- VAERD!!!
- It will take years before its available!
- The flu may be too smart!



Rational for vaccination


| 5/H7 virus density | Index case flock | Evidence of spread to industrial sector | Population density in area | Policy |
|-----------------------|---------------------|--|-------------------------------|--------------|
| HPAI/LPAI | Backyard | No | High/Low | Stamping-out |
| HPAI/LPAI | Backyard | Yes | Low | Stamping-out |
| | | | High | Vaccination |
| HPAI/LPAI | Industrial | No | | Stamping-out |
| HPAI/LPAI | Industrial | Yes | Low | |
| | | | High | Vaccination |

In all cases - also consider zoonotic risk!

99% of avian influenza vaccines are used in four countries: China (90 %), Egypt, Vietnam and Indonesia

Ilaria Capua¹ & Stefano Marangon²

Successful vaccination




Vaccination against LPAI

- **Vaccination against enzootic LPAI – examples**
 - Mexico vaccinate chicken against LPAI H5N2
 - Has been used temporarily for Turkeys in the US and Canada
 - Vaccination against LPAI H9 in Asia and Middle East
 - H7 vaccines were used in Italy 2000-20002 to eradicate the H7N1 LPAI virus
- **Can LPAI vaccination “hide” introductions of HPAI?**


Vaccination against LPAI in non-enzootic regions

Which virus?




Vaccination against enzootic HPAI H5

- Vaccination against H5N1 has been performed in several countries in Asia and Middle East for a number of years
- Human cases of H5N1 are declining, but still a high number of H5N1 and H5 reassortments (H5N8, H5N2, H5N6) detected globally




Also in Europe!



Will HPAI H5 become enzootic in wild birds in Europe?



H5 is a moving target – making vaccination difficult



Antigenic drift and vaccine efficacy (VE)

Vaccine 35 (2017) 4859–4869




ELSEVIER

Contents lists available at [ScienceDirect](https://www.sciencedirect.com)

Vaccine

journal homepage: www.elsevier.com/locate/vaccine



Review

Vaccine efficacy against Indonesian Highly Pathogenic Avian Influenza H5N1: systematic review and meta-analysis



Juan P. Villanueva-Cabezas ^{a,b,*}, Mauricio J.C. Coppo ^c, Peter A. Durr ^b, Jodie McVernon ^{a,d,e}

^aModelling and Simulation Unit, Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Carlton, Victoria, Australia

^bAustralian Animal Health Laboratory, CSIRO, Geelong, Victoria, Australia

^cAsia-Pacific Centre for Animal Health, Faculty of Veterinary and Agricultural Sciences, The University of Melbourne, Parkville, Victoria, Australia


^dVictorian Infectious Disease Reference Laboratory, The Royal Melbourne Hospital and The University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Victoria, Australia

^eMurdoch Children's Research Institute, Royal Children's Hospital, Parkville, Victoria, Australia

We conclude that the VE of commercial vaccines in Indonesia changes as Indonesian HPAI/H5N1 evolve into new clades, which should warrant continuous matching between vaccine-seeds and emerging HPAI/H5N1. Furthermore, given the characteristics of the new Indonesian dominant HPAI/H5N1 clade, further studies to confirm VE across species are warranted.

Vaccination of poultry to prevent human cases: H7N9

Number of Confirmed Human H7N9 Cases
by week as of 2018-8-31




Vaccination in Europe to prevent HPAI?

- Impossible to predict which strain that will be next – difficult to prepare vaccine stocks up front
- Classical vaccines takes 22-26 weeks to produce – chasing the tail of the dog!
- If H5XN becomes enzootic in wild birds in Europe it would be easier to select a homologueous vaccine strain – but still need for regular updates
- Cost-benefit positive or negative?
 - Cost of vaccines
 - Cost of monitoring
 - Trade consequences




Monitoring in vaccinated areas (example from Italy 2002)

MONITORING MEASURES IN THE VACCINATION AREA






Influenza A in swine


- Important veterinary disease
- Highly prevalent in most countries
- Zoonotic potential
- Available vaccines contains 10-15 years old isolates



Evolution of influenza A virus




Previous human pandemics +/- swine?




Pandemic 2009H1N1 - origin

Gene Segments, Hosts, and Years of Introduction



Reassortments

Human seasonal influenza: **N2hu95**, **H3hu05**, **H3hu16**




In Germany – 35 different variants of influenza in swine

In China more than 100 different variants


Several reports on zoonotic transmission

Triple-reassortant influenza A virus with H3 of human seasonal origin, NA of swine origin, and internal A(H1N1) pandemic 2009 genes is established in Danish pigs


Jesper Schak Krog¹  | Charlotte Kristiane Hjulsager¹ | Michael Albin Larsen² |
Lars Erik Larsen¹



Swine influenza subtypes globally



Live Hog Exports




Reference: www.offlu.com

Influenza in mink



| | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 |
|----------------------|------------|---------------|---------------|------|---------------|--|------|--------------------------------|-------------|
| No of submissions | 54 | 9 | 7 | 5 | 18 | 42 | 6 | 25 | 15 |
| Positive submissions | 25 | 6 | 1 | 0 | 8 | 30 | 1 | 16 | 7 |
| Subtype | H3N2 | H1pdm09 (n=4) | H1pdm09 (n=1) | - | H1pdm09 (n=6) | H1pdm09 (n=22) H1N1sw (n=1) H1N2sw (n=2) | | H1pdm09 (n=12) H1N2sw (n=1) | Not H1pdm09 |
| Positive, season | 29/9-30/10 | 3/8-14/9 | 12/10 | - | 10/9-6/11 | 30/9-26/11 | 9/10 | 11/5-22/11 | 8/9-13/10 |

Influenza in mink from humans – also during summer!




Swine avH1N1, avH1N2
Mink 2014 + 2016

H1N1pdm
Mink 2014 + 2016

Swine
human

0.05

Transmissions – human influenza genes found in mink



Surveillance and legislation in EU

- **Avian influenza**

- Passive surveillance in poultry etc – **mandatory**
- Active surveillance in poultry and wild birds – **mandatory**
- Active surveillance in wild birds
 - **Not mandatory**
 - National programs if any
 - No EU coordination nor mandatory reporting system
- Consequence of detection in poultry etc.
 - Eradication even for LPAI without zoonotic potential
 - Is this necessary/ ethical sound/cost effective?

- **Swine influenza and influenza in mink etc.**

- **No** requirement nor support for surveillance
- **No** EU involvement
- **No** follow-up on detection of strains with zoonotic potential
- **No** formalized system for exchange of data

Room for improvement for handling of influenza virus in Europe – personal view!

- Wild bird surveillance – joint EU surveillance with focus on hot spots
- More research on wild bird migrations routes
- Compartmentalization of sectors should be implemented
- EU should support and coordinate surveillance in other species including swine
- Detection of influenza virus in animals with human influenza genes should be notifiable
- Mandatory sharing of sequence data of influenza virus from all species should be mandatory
- EMA should allow fast update of vaccine strains in swine influenza vaccines– presently it takes 5 years to change the viral strains

Thank you for the attention

